| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 412 | 525 | 519 | 483 | 486 | 545 | 489 | 565 | 542 | 599 | 531 | 637 | 555 | 714 | 732 | 841 | 981 | 1,144 | 1,295 | 1,417 | 1,284 | 1,206 | 1,034 | 1,426 | 1,541 | 1,577 | 1,546 | 1,383 | 1,185 | 1,226 | 1,197 | 1,458 | 1,197 | 1,228 | 1,425 | 1,779 |
| Expenses | 325 | 408 | 406 | 358 | 382 | 426 | 392 | 443 | 459 | 513 | 442 | 523 | 467 | 575 | 581 | 647 | 696 | 765 | 862 | 940 | 883 | 858 | 744 | 1,028 | 1,085 | 1,127 | 1,141 | 1,095 | 1,015 | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 |
| EBITDA | 87 | 116 | 112 | 125 | 104 | 119 | 97 | 122 | 83 | 86 | 89 | 114 | 88 | 139 | 150 | 194 | 285 | 379 | 433 | 477 | 401 | 348 | 291 | 398 | 456 | 450 | 405 | 287 | 170 | 190 | 184 | 260 | 174 | 183 | 295 | 479 |
| Operating Profit % | 21 % | 21 % | 20 % | 24 % | 20 % | 21 % | 18 % | 21 % | 15 % | 13 % | 17 % | 18 % | 15 % | 19 % | 20 % | 23 % | 29 % | 33 % | 33 % | 33 % | 31 % | 29 % | 28 % | 28 % | 30 % | 28 % | 26 % | 21 % | 14 % | 15 % | 15 % | 17 % | 14 % | 15 % | 20 % | 24 % |
| Depreciation | 25 | 26 | 27 | 28 | 30 | 30 | 31 | 35 | 38 | 40 | 43 | 44 | 46 | 48 | 48 | 46 | 49 | 51 | 52 | 54 | 59 | 63 | 64 | 66 | 71 | 82 | 84 | 87 | 91 | 93 | 98 | 102 | 106 | 108 | 106 | 110 |
| Interest | 28 | 25 | 31 | 17 | 19 | 20 | 18 | 23 | 22 | 25 | 24 | 18 | 23 | 26 | 21 | 21 | 15 | 14 | 17 | 22 | 27 | 22 | 23 | 31 | 29 | 40 | 43 | 53 | 39 | 42 | 51 | 51 | 49 | 53 | 58 | 56 |
| Profit Before Tax | 35 | 66 | 54 | 81 | 55 | 70 | 49 | 64 | 23 | 22 | 23 | 53 | 19 | 66 | 82 | 127 | 222 | 314 | 364 | 401 | 316 | 263 | 204 | 302 | 356 | 328 | 278 | 147 | 41 | 54 | 35 | 107 | 19 | 23 | 131 | 312 |
| Tax | 9 | 18 | 9 | 9 | 16 | 21 | 14 | 19 | 6 | 6 | 5 | 9 | 4 | 9 | 8 | 17 | 50 | 72 | 91 | 104 | 74 | 59 | 49 | 70 | 104 | 95 | 75 | 42 | 14 | 17 | 11 | 32 | 6 | 3 | 38 | 80 |
| Net Profit | 26 | 48 | 45 | 71 | 39 | 49 | 35 | 45 | 17 | 16 | 18 | 43 | 15 | 57 | 74 | 110 | 172 | 242 | 273 | 297 | 242 | 204 | 155 | 232 | 252 | 233 | 203 | 105 | 27 | 37 | 23 | 75 | 13 | 20 | 93 | 233 |
| EPS in ₹ | 3.73 | 5.18 | 4.50 | 6.75 | 3.68 | 4.61 | 3.29 | 4.26 | 1.56 | 1.53 | 1.67 | 4.07 | 1.42 | 1.06 | 1.38 | 2.06 | 3.21 | 4.53 | 5.09 | 5.53 | 4.50 | 3.76 | 2.87 | 4.29 | 4.68 | 4.33 | 3.78 | 1.90 | 0.46 | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.34 |
Laurus Labs
617.80
-2.75
(-0.44%)
Market Cap
33,315.02 Cr
EPS
2.98
PE Ratio
93.43
Dividend Yield
0.13 %
Industry
Healthcare52 Week High
660.90
52 Week Low
385.45
PB Ratio
7.48
Debt to Equity
0.56
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,836.60 | #1 4,40,661.86 | 37.20 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 62.24 | |
6,124.50 | 1,62,586.23 | 78.35 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 60.86 | |
1,542.90 | 1,24,606.91 | 24.70 | 26,520.70 | 14.17 | 4,155 | 47.38 | 57.59 | |
3,285.20 | 1,11,186.10 | 59.18 | 10,785.70 | 11.59 | 1,656 | 13.54 | 54.31 | |
2,415.40 | 99,654.22 | 48.14 | 10,615.60 | 19.57 | 1,942 | -16.38 | 46.37 | |
1,171.30 | 97,739.76 | #1 18.38 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.52 | |
2,085.30 | 95,202.48 | 32.75 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 54.25 | |
892.50 | 89,806.38 | 19.65 | 19,831.50 | 13.82 | 3,831 | 29.92 | 53.95 | |
1,242.00 | 72,135.56 | 19.97 | 29,559.20 | 17.55 | 3,169 | -10.04 | 59.05 | |
30,725.00 | 65,288.48 | 48.97 | 6,097.20 | 10.80 | 1,201 | 16.01 | 55.94 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-16.20 %
Net Income Growth
-78.89 %
Cash Flow Change
-33.02 %
ROE
-79.22 %
ROCE
-67.38 %
EBITDA Margin (Avg.)
-39.99 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 |
| Fixed Assets | 801 | 1,021 | 1,230 | 1,481 | 1,629 | 1,726 | 2,171 | 2,653 | 3,409 | 3,890 |
| Current Assets | 865 | 1,003 | 1,140 | 1,248 | 1,463 | 1,812 | 3,075 | 3,345 | 3,462 | 3,835 |
| Capital Work in Progress | 110 | 70 | 143 | 163 | 110 | 67 | 362 | 813 | 551 | 423 |
| Investments | 0 | 7 | 3 | 3 | 3 | 3 | 3 | 31 | 50 | 124 |
| Other Assets | 983 | 1,126 | 1,277 | 1,369 | 1,589 | 1,953 | 3,215 | 3,472 | 3,651 | 3,950 |
| Total Liabilities | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 |
| Current Liabilities | 805 | 884 | 1,121 | 1,307 | 1,424 | 1,692 | 2,457 | 2,681 | 2,432 | 3,112 |
| Non Current Liabilities | 365 | 483 | 202 | 227 | 349 | 288 | 693 | 928 | 1,180 | 1,159 |
| Total Equity | 724 | 857 | 1,330 | 1,483 | 1,558 | 1,770 | 2,601 | 3,359 | 4,049 | 4,116 |
| Reserve & Surplus | 642 | 774 | 1,225 | 1,371 | 1,447 | 1,658 | 2,490 | 3,244 | 3,930 | 4,003 |
| Share Capital | 82 | 82 | 106 | 106 | 106 | 107 | 107 | 108 | 108 | 108 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 24 | -27 | -10 | 1 | 0 | -1 | 47 | 27 | -30 | 93 |
| Investing Activities | -397 | -312 | -289 | -384 | -253 | -221 | -941 | -915 | -997 | -822 |
| Operating Activities | -65 | 182 | 332 | 343 | 298 | 347 | 733 | 911 | 994 | 666 |
| Financing Activities | 486 | 103 | -54 | 42 | -45 | -128 | 255 | 30 | -27 | 250 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 27.45 % | 27.30 % | 27.30 % | 27.27 % | 27.27 % | 27.27 % | 27.27 % | 27.20 % | 27.20 % | 27.20 % | 27.20 % | 27.19 % | 27.19 % | 27.18 % | 27.18 % | 27.62 % | 27.62 % |
| FIIs | 0.00 % | 0.04 % | 0.04 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 25.97 % | 25.67 % | 26.08 % | 25.56 % | 25.52 % |
| DIIs | 2.06 % | 2.40 % | 2.11 % | 2.77 % | 3.51 % | 4.77 % | 8.98 % | 9.51 % | 9.74 % | 10.14 % | 10.71 % | 10.77 % | 11.77 % | 13.56 % | 13.05 % | 12.74 % | 11.77 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 34.17 % | 34.18 % | 32.91 % | 32.87 % | 31.15 % | 28.42 % | 27.96 % | 28.95 % | 28.49 % | 28.26 % | 26.49 % | 25.01 % | 23.95 % | 22.68 % | 22.67 % | 22.72 % | 23.65 % |
| Others | 36.32 % | 36.07 % | 37.65 % | 37.08 % | 38.05 % | 39.53 % | 35.80 % | 34.32 % | 34.55 % | 34.39 % | 35.60 % | 37.03 % | 11.12 % | 10.91 % | 11.03 % | 11.36 % | 11.44 % |
| No of Share Holders | 2,35,836 | 2,99,257 | 3,94,053 | 4,67,419 | 4,27,465 | 4,07,186 | 3,90,695 | 4,23,931 | 4,18,615 | 4,17,977 | 4,02,640 | 3,82,880 | 3,56,830 | 3,24,059 | 3,09,063 | 2,92,214 | 2,92,905 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1.5 | 1.5 | 1.5 | 2.5 | 2 | 2 | 2 | 0.8 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.49 | 1.88 | 2.31 | 0.69 | 0.34 | 0.67 | 0.51 | 0.13 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 May 2025 |  Dividend | ₹ 0.80 /share | 09 May 2025 | 650.45 | 620.35 |
| 24 Apr 2025 |  Quarterly Result Announcement | NA | 24 Apr 2025 | 564.25 | 650.45 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 611.75 | 585.15 |
| 06 Nov 2024 | Dividend | ₹ 0.40 /share | 06 Nov 2024 | 449.35 | 489.25 |
| 24 Oct 2024 | Quarterly Result Announcement | NA | 24 Oct 2024 | 480.30 | 449.35 |
| 11 Jul 2024 |  Annual General Meeting | NA | 11 Jul 2024 | 434.40 | 472.50 |
| 08 May 2024 | Dividend | ₹ 0.40 /share | 08 May 2024 | 434.40 | 429.45 |
| 02 Nov 2023 | Dividend | ₹ 0.40 /share | 02 Nov 2023 | 396.40 | 358.90 |
| 10 May 2023 | Dividend | ₹ 1.20 /share | 10 May 2023 | 300.05 | 334.30 |
| 04 Nov 2022 | Dividend | ₹ 0.80 /share | 03 Nov 2022 | 526.20 | 477.75 |
| 11 May 2022 | Dividend | ₹ 1.20 /share | 10 May 2022 | 578.80 | 525.10 |
| 18 Nov 2021 | Dividend | ₹ 0.80 /share | 17 Nov 2021 | 574.90 | 484.00 |
| 12 May 2021 | Dividend | ₹ 0.80 /share | 11 May 2021 | 474.45 | 491.75 |
| 09 Feb 2021 | Dividend | ₹ 0.40 /share | 08 Feb 2021 | 366.20 | 356.95 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationApr 24, 2025
Apr 24, 2025Corporate Action-Board approves DividendApr 24, 2025
Apr 24, 2025Board Meeting Outcome for Board Meeting Outcome - 24.04.2025Apr 24, 2025
Apr 24, 2025Results - Year Ended March 31 2025Apr 24, 2025
Apr 24, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 10, 2025
Apr 10, 2025Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended March 31 2025 And Payment Of 2Nd Interim Dividend For FY 2024-25Apr 10, 2025
Apr 10, 2025Corrigendum To Intimation Of Grant Of Stock Options To The Eligible Employees Dated 28.03.2025Mar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 28, 2025
Mar 28, 2025Intimation Of Re-Appointment Of Executive Directors Of The Company Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 28, 2025
Mar 28, 2025Intimation Of Grant Of Stock Options To The Eligible EmployeesMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 15, 2025
Mar 15, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 31, 2025
Jan 31, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 27, 2025
Jan 27, 2025Rumour verification - Regulation 30(11)Jan 27, 2025
Jan 27, 2025Clarification sought from Laurus Labs LtdJan 27, 2025
Jan 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Jan 24, 2025Results For The Quarter Ended 31.12.2024Jan 24, 2025
Jan 24, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 22, 2025
Jan 22, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Jan 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Jan 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Jan 08, 2025Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 06, 2025
Jan 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 31, 2024
Dec 31, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 06, 2024
Dec 06, 2024Announcement under Regulation 30 (LODR)-AcquisitionDec 06, 2024
Dec 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 27, 2024
Nov 27, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 25, 2024
Oct 25, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 24, 2024
Oct 24, 2024General UpdatesOct 24, 2024
Oct 24, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2024
Oct 24, 2024Announcement under Regulation 30 (LODR)-Investor PresentationOct 24, 2024
Oct 24, 2024Corporate Action-Board approves DividendOct 24, 2024
Oct 24, 2024Board Meeting Outcome for Interim Dividend FY 2024-25Oct 24, 2024
Oct 24, 2024Results - Half Year Ended September 30, 2024Oct 24, 2024
Oct 24, 2024Technical Indicators
RSI(14)
Neutral 51.82
ATR(14)
Less Volatile 23.30
STOCH(9,6)
Neutral 30.00
STOCH RSI(14)
Neutral 30.52
MACD(12,26)
Bearish -2.57
ADX(14)
Weak Trend 12.44
UO(9)
Bearish 45.17
ROC(12)
Downtrend And Accelerating -1.18
WillR(14)
Neutral -51.31
About Laurus Labs
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Listing Date
19 Dec, 2016(8 Years,
17 days)
Website
Chairperson NameRavindranath Kancherla
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
